{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:02:54Z","timestamp":1794013374246,"version":"4.8.0"},"reference-count":171,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/1744666x.2026.2665732","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:45:39Z","timestamp":1777308339000},"page":"445-462","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9450-1753","authenticated-orcid":false,"given":"Meng Jie","family":"Ho","sequence":"first","affiliation":[{"name":"Duke-NUS Medical School","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5127-3767","authenticated-orcid":false,"given":"Choon Fong","family":"Liew","sequence":"additional","affiliation":[{"name":"Mount Elizabeth Medical Centre","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0136-7341","authenticated-orcid":false,"given":"Nguan Soon","family":"Tan","sequence":"additional","affiliation":[{"name":"Nanyang Technological University","place":["Singapore, Singapore"]},{"name":"Nanyang Technological University","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Nagoya City University Graduate School of Medical Sciences","place":["Nagoya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7607-3124","authenticated-orcid":false,"given":"Hazel H.","family":"Oon","sequence":"additional","affiliation":[{"name":"Nanyang Technological University","place":["Singapore, Singapore"]},{"name":"National Skin Centre and Skin Research Institute of Singapore (SRIS)","place":["Singapore, Singapore"]},{"name":"National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70005"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.51"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13888"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1678"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.22070"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03677-4"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.027"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02105-1"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2025-0148"},{"key":"e_1_3_5_12_1","doi-asserted-by":"crossref","unstructured":"Tirzepatide a new era of dual-targeted treatment for diabetes and obesity: a mini-review [Internet]. [cited 2025 Nov 25]. Available from: https:\/\/www.mdpi.com\/1420-3049\/27\/13\/4315","DOI":"10.3390\/molecules27134315"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.033"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61111902"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70058"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00788"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1593003"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0333010"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-04443-0"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000544023"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjad211"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-011-0359-9"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2011.11.004"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12380"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1530\/edm-23-0017"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-21-0007"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12886"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04609.x"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1826392"},{"key":"e_1_3_5_32_1","unstructured":"Lilly\u2019s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind phase 3b trial for adults with active psoriatic arthritis and obesity or overweight. Eli Lilly and Company. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together"},{"key":"e_1_3_5_33_1","unstructured":"NCT06588283. Ixekizumab concomitantly administered with tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight [Internet]. 2024. Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02755932\/full"},{"key":"e_1_3_5_34_1","unstructured":"Lilly\u2019s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind phase 3b trial for adults with psoriasis and obesity or overweight. Eli Lilly and Company. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-0"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16527"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12629"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15233"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000473873"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.11.007"},{"key":"e_1_3_5_40_1","article-title":"Single-center proof of concept study evaluating the efficacy and safety of tirzepatide for moderate to severe hidradenitis suppurativa","author":"An Open-Label","unstructured":"An Open-Label. Single-center proof of concept study evaluating the efficacy and safety of tirzepatide for moderate to severe hidradenitis suppurativa. JD Don J Drugs Dermatol.","journal-title":"JD Don J Drugs Dermatol"},{"key":"e_1_3_5_41_1","unstructured":"DailyMed - LIRAGLUTIDE injection [Internet]. 2025. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=0450d8a2-a88e-4849-9788-ed4f5246f223"},{"key":"e_1_3_5_42_1","unstructured":"DailyMed - LIRAGLUTIDE injection [Internet]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=14bf9812-14ee-46ce-93b1-686e4906cbbc"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3148"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.0000000000000149"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.06.010"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae105"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae398"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.08.018"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.2174\/011871530336108925032000246"},{"key":"e_1_3_5_50_1","unstructured":"Dermatology. Bullous pemphigoid triggered by liraglutide | MDedge [Internet]. Available from: https:\/\/mdedge.com\/dermatology\/article\/240500\/mixed-topics\/bullous-pemphigoid-triggered-liraglutide"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1893"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2012.05.018"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.208.Supp.48.13"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155"},{"key":"e_1_3_5_55_1","unstructured":"Type 2 Diabetes Medicine | RYBELSUS\u00ae (semaglutide) tablets [Internet]. Available from: https:\/\/www.rybelsus.com\/"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10816"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258"},{"key":"e_1_3_5_58_1","unstructured":"MASH management | wegovy\u00ae (semaglutide) injection 2.4 mg [Internet]. Available from: https:\/\/mash.wegovy.com\/"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.4657"},{"key":"e_1_3_5_60_1","unstructured":"Dosing schedule | ozempic\u00ae (semaglutide) injection [Internet]. Available from: https:\/\/www.ozempic.com\/how-to-take\/ozempic-dosing.html"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0668-z"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.10.012"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.05.036"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.02.014"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds20-0033"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaf008"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55324"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81663"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.05.005"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.07.027"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2386047"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.06.012"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17246"},{"key":"e_1_3_5_76_1","unstructured":"Drugs.com [Internet]. Tanzeum (albiglutide) FDA approval history. Available from: https:\/\/www.drugs.com\/history\/tanzeum.html"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0499-8"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2016.1240780"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0024"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3360-3"},{"key":"e_1_3_5_81_1","unstructured":"Monaco K Writer S Today M. Withdrawn diabetes drug worked in secondary CV prevention [Internet]. 2018. Available from: https:\/\/www.medpagetoday.com\/cardiology\/prevention\/75501"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2801"},{"key":"e_1_3_5_83_1","unstructured":"DailyMed - TRULICITY- dulaglutide injection solution [Internet]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20041"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21536"},{"issue":"4","key":"e_1_3_5_87_1","first-page":"13","article-title":"A CASE OF morbilliform drug eruption to dulaglutide","volume":"13","author":"Rzepka PV","year":"2020","unstructured":"Rzepka PV, Kaffenberger JA. A CASE OF morbilliform drug eruption to dulaglutide. J Clin Aesthet Dermatol. 2020;13(4):13. PubMed PMID: 33144906; PubMed Central PMCID: PMC7605389.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2024.101552"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.13799"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2023.9676"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14272"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.07.003"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13072"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2006"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12328"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2014.01.012"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02121-5"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05715-4"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.07.017"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-02870"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50112"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51460"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45181"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.02.018"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18879"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1282463"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.10.008"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.28.4.283"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13266"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12246"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14193"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2020.32.3.230"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000243"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000036"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235663"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1177\/8755122514539462"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030805"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2010.12.016"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104766"},{"key":"e_1_3_5_121_1","unstructured":"Pfizer. A phase 1 OPEN-LABEL FIXED-SEQUENCE study to estimate the effect OF PF-07081532 administration on the SINGLE-DOSE pharmacokinetics OF DABIGATRAN and ROSUVASTATIN in overweight or obese adult participants [clinical trial registration] [Internet]. Clinical trial registration No.: nCT05788328. clinicaltrials.gov; 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05788328"},{"key":"e_1_3_5_122_1","unstructured":"Pfizer. A phase 2B randomized DOUBLE-BLIND PLACEBO-CONTROLLED parallel group DOSE-RANGING study to evaluate the efficacy and safety OF PF-06882961 administration in adults with obesity [clinical trial registration] [Internet]. OctClinical trial registration No.: nCT04707313. clinicaltrials.gov; 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04707313"},{"key":"e_1_3_5_123_1","unstructured":"Effects of AZD5004 in adults who are living with obesity or overweight with at least 1 weight-related comorbidity [Internet]. Available from: https:\/\/www.astrazenecaclinicaltrials.com\/study\/D7260C00001"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16610"},{"key":"e_1_3_5_125_1","unstructured":"Genentech: press releases. 2024 Available from: https:\/\/www.gene.com\/media\/press-releases\/15032\/2024-07-16\/genentech-announces-positive-phase-i-res"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm93020026"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103683"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15383"},{"key":"e_1_3_5_129_1","unstructured":"Study details - Gilead clinical trials [Internet]. Available from: https:\/\/www.gileadclinicaltrials.com\/study?nctid=NCT06562907"},{"key":"e_1_3_5_130_1","unstructured":"Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron | Pfizer [Internet]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-provides-update-oral-glp-1-receptor-agonist"},{"key":"e_1_3_5_131_1","unstructured":"Pfizer provides update on GLP-1-RA clinical development program for adults with obesity and type 2 diabetes mellitus | pfizer [Internet]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-provides-update-glp-1-ra-clinical-development"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505669"},{"key":"e_1_3_5_133_1","unstructured":"Eli Lilly and Company. A phase 2 study of once-daily LY3502970 compared with placebo in participants who have obesity or are overweight with weight-related comorbidities [clinical trial registration] [Internet]. Clinical trial registration No.: nCT05051579. clinicaltrials.gov; 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05051579"},{"key":"e_1_3_5_134_1","unstructured":"Eli Lilly and Company. A phase 2 study of once-daily LY3502970 compared with placebo and once-weekly dulaglutide in participants with type 2 diabetes mellitus [clinical trial registration] [Internet]. SepClinical trial registration No.: nCT05048719. clinicaltrials.gov; 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05048719"},{"key":"e_1_3_5_135_1","unstructured":"Gan & Lee Pharmaceuticals. A phase ii clinical study to compare the efficacy and safety of once-weekly GZR102 injection and Bi-weekly GZR18 injection in type 2 diabetes mellitus with inadequate glycemic control on GLP-1 receptor agonists with or without Oral antidiabetic drugs [clinical trial registration] [Internet]. NovClinical trial registration No.: nCT07055386 clinicaltrials.gov; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07055386"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-023-00966-w"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00845-X"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502082"},{"key":"e_1_3_5_139_1","unstructured":"Merck Sharp & Dohme LLC. A phase 2a randomized active-comparator-controlled open-label study to evaluate the efficacy and safety of efinopegdutide (MK-6024) in individuals with nonalcoholic fatty liver disease [clinical trial registration] [Internet]. OctClinical trial registration No.: nCT04944992. clinicaltrials.gov; 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04944992"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1309118"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2472408"},{"key":"e_1_3_5_143_1","unstructured":"Viking Therapeutics InvestorRoom [Internet]. Viking therapeutics announces positive Top-Line Results from phase 2 VENTURE-Oral dosing trial of VK2735 Tablet formulation in patients with obesity. Available from: https:\/\/ir.vikingtherapeutics.com\/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14712"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972"},{"key":"e_1_3_5_146_1","unstructured":"Boehringer I. A phase II randomized Double blind parallel Group 46\u00a0weeks dose-finding study of BI 456906 administered Once weekly subcutaneously compared with placebo in patients with obesity or overweight [clinical trial registration] [Internet]. Clinical trial registration No.: nCT04667377. clinicaltrials.gov; 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04667377"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411528"},{"key":"e_1_3_5_148_1","unstructured":"AstraZeneca. A phase ii randomized Double-blind placebo-controlled proof-of-concept study to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis [clinical trial registration] [Internet]. AugClinical trial registration No.: nCT05364931. clinicaltrials.gov; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05364931"},{"key":"e_1_3_5_149_1","unstructured":"AstraZeneca. A phase 2b multicentre randomised double-blind placebo-controlled and open-label comparator study of cotadutide in participants who have chronic kidney disease with type 2 diabetes mellitus [clinical trial registration] [Internet]. Clinical trial registration No.: nCT04515849. clinicaltrials.gov; 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04515849"},{"key":"e_1_3_5_150_1","unstructured":"MedImmune LLC. A phase 2 randomized Double-blind placebo-controlled study to evaluate the safety and pharmacodynamic effects of MEDI0382 in obese subjects with non-alcoholic fatty liver disease (NAFLD)\/ non-alcoholic steatohepatitis (NASH) [clinical trial registration] [Internet]. Dec clinical trial registration No.: nCT04019561. clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04019561"},{"key":"e_1_3_5_151_1","unstructured":"MedImmune LLC. A phase 2a randomized blinded placebo-controlled study to evaluate the safety tolerability pharmacokinetics and efficacy of MEDI0382 in overweight\/obese subjects with type 2 diabetes mellitus [clinical trial registration] [Internet]. Clinical trial registration No.: nCT03745937. clinicaltrials.gov; 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03745937"},{"key":"e_1_3_5_152_1","unstructured":"AstraZeneca. A phase IIa randomised parallel Double-blind Placebo-controlled study to evaluate the safety efficacy and pharmacokinetics of MEDI0382 in Japanese preobese or obese subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise [clinical trial registration] [Internet]. Clinical trial registration No.: nCT03645421. clinicaltrials.gov; 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03645421"},{"key":"e_1_3_5_153_1","unstructured":"MedImmune LLC. An exploratory phase 2 randomised Double-blind placebo-controlled and open-label active comparator study to evaluate the effect of MEDI0382 on hepatic glycogen metabolism in overweight and obese subjects with type 2 diabetes mellitus. [clinical trial registration] [Internet]. Clinical trial registration No.: nCT03555994. clinicaltrials.gov; 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03555994"},{"key":"e_1_3_5_154_1","unstructured":"MedImmune LLC. A phase 2a randomised Double-blind placebo-controlled study to evaluate the efficacy safety and pharmacokinetics of MEDI0382 in subjects with type 2 diabetes mellitus and renal impairment [clinical trial registration] [Internet]. Clinical trial registration No.: nCT03550378. clinicaltrials.gov; 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03550378"},{"key":"e_1_3_5_155_1","unstructured":"MedImmune LLC. A phase 2 randomised Double-blind placebo-controlled study to evaluate the efficacy safety tolerability and pharmacokinetics of different doses of MEDI0382 in overweight and obese subjects with type 2 diabetes mellitus [clinical trial registration] [Internet]. Clinical trial registration No.: nCT03244800. clinicaltrials.gov; 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03244800"},{"key":"e_1_3_5_156_1","unstructured":"AstraZeneca. A phase IIb randomised parallel Double-blind placebo-controlled and open-label active comparator study to evaluate the efficacy and safety of MEDI0382 in the treatment of overweight and obese subjects with type 2 diabetes mellitus [clinical trial registration] [Internet]. Clinical trial registration No.: nCT03235050. clinicaltrials.gov; 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03235050"},{"key":"e_1_3_5_157_1","unstructured":"MedImmune LLC. A phase 1\/2 randomized Double-blind placebo-controlled multiple-ascending-dose study to evaluate the efficacy safety and pharmacokinetics of MEDI0382 in overweight and obese subjects with a history of type 2 diabetes mellitus [clinical trial registration] [Internet]. Clinical trial registration No.: nCT02548585. clinicaltrials.gov; 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02548585"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70584"},{"key":"e_1_3_5_159_1","unstructured":"\u2018Ozempic face\u2019 may be driving a cosmetic surgery boom | CNN [Internet]. Available from: https:\/\/edition.cnn.com\/2025\/07\/30\/style\/ozempic-face-cosmetic-surgery"},{"key":"e_1_3_5_160_1","unstructured":"What is \u201cozempic face\u201d? Before and after [Internet]. Available from: https:\/\/www.medicalnewstoday.com\/articles\/ozempic-face"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-025-04293-w"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjae132"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.02.009"},{"key":"e_1_3_5_164_1","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000143"},{"key":"e_1_3_5_165_1","doi-asserted-by":"crossref","unstructured":"Akiska YM Vidal SI Menta N et al. Increased incidence and risk of hair loss with glucagon-like peptide 1 receptor agonists: a real-world multicentre cohort study [Internet]. 2025. Available from: https:\/\/www.emjreviews.com\/dermatology\/abstract\/increased-incidence-and-risk-of-hair-loss-with-glucagon-like-peptide-1-receptor-agonists-a-real-world-multicentre-cohort-study-j030123\/","DOI":"10.33590\/emjdermatol\/TYEW1122"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202403343R"},{"key":"e_1_3_5_167_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03257-w"},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf361"},{"key":"e_1_3_5_169_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20197"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13544"},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.11817\/j.issn.1672-7347.2023.230100"},{"key":"e_1_3_5_172_1","unstructured":"View of epidermal insulin resistance as a therapeutic target in acanthosis nigricans? Available from: https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/6441\/9704"},{"key":"e_1_3_5_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.06.355"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2026.2665732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:10:42Z","timestamp":1781680242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2026.2665732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":171,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/1744666X.2026.2665732"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2026.2665732","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}